<DOC>
	<DOCNO>NCT01696032</DOCNO>
	<brief_summary>A 2-part , Phase 1-2 control , open-label , randomize study patient platinum-resistant recurrent ovarian cancer . In Part 1 , patient receive SGI-110 carboplatin . The optimum dose identify Part 1 base safety efficacy . In Part 2 , patient randomize receive dose identify Part 1 plus carboplatin one three treatment choice discretion investigator . The treatment choice consist topotecan , pegylated liposomal doxorubicin , paclitaxel .</brief_summary>
	<brief_title>SGI-110 Combination With Carboplatin Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Patients woman 18 year age old . 2 . Patients histologically cytologically confirm recurrent highgrade serous epithelial ovarian cancer ( Grade 2 3 ) , primary peritoneal carcinomatosis fallopian tube cancer . 3 . Patients platinumresistant disease ( define relapse within 6 month last platinumcontaining regimen ) . There limit number prior treatment regimen Part 1 . In Part 2 , patient may 3 prior cytotoxic treatment regimen , exclude adjuvant maintenance therapy . 4 . Patients must prior paclitaxel treatment . 5 . Patients measurable disease accord RECIST v1.1 detectable disease . 6 . Patients ECOG performance status 0 1 . 7 . Patients acceptable organ function . 8 . Patients must least 3 week last chemotherapy . 1 . Patients hypersensitivity SGI110 and/or carboplatin component drug product . 2 . Patients receive prior therapy hypomethylating agent . 3 . Patients refractory platinum treatment i.e. , progress platinum treatment . 4 . Patients abnormal leave ventricular ejection fraction . 5 . Patients Grade 2 great neuropathy . 6 . Patients know brain metastasis . 7 . Patients known history HIV , HCV HBV .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>